ALFA Filings
Every announcement, straight from the exchange
Every OneSource Specialty Pharma other announcement announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements
Onesource Specialty Pharma Ltd submitted its quarterly shareholding pattern in compliance with SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Onesource Specialty Pharma Ltd refiled its shareholding pattern for the quarter ended June 30, 2025, to ensure uniformity across exchanges following regulatory remarks.
OneSource Specialty Pharma Ltd appointed M/s B S R & Co LLP as its Statutory Auditors for a five-year term ending at the 24th AGM.
OneSource Specialty Pharma Limited has submitted its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026, as required by regulation.
Onesource Specialty Pharma Ltd has submitted its quarterly shareholding pattern for the quarter ended June 30, 2026. This filing provides details on the company's equity ownership distribution.
OneSource Specialty Pharma's partner, Orbicular Pharmaceutical Technologies, received tentative U.S. FDA approval for a generic version of Ozempic (Semaglutide Injection). OneSource served as the CDMO partner providing end-to-end manufacturing from its Bangalore facility. This milestone validates OneSource's specialized manufacturing capabilities for complex peptides and injectables.
OneSource Specialty Pharma Limited received an ESG Rating of '73' (Category: Leader) from NSE Sustainability Ratings & Analytics Limited for FY25. The rating was independently assigned based on publicly available information. This recognition highlights the company's commitment to Environmental, Social, and Governance standards.